Canakinumab Subcutaneous and Insulin aspart, recombinant Subcutaneous
Determining the interaction of Canakinumab Subcutaneous and Insulin aspart, recombinant Subcutaneous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: canakinumab
Brand name: Ilaris
Synonyms: Canakinumab
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Canakinumab Subcutaneous-Insulin degludec
- Canakinumab Subcutaneous-Insulin Degludec (U-100) Prefilled Pens
- Canakinumab Subcutaneous-Insulin Degludec (U-100) Vials
- Canakinumab Subcutaneous-Insulin Degludec (U-200) Prefilled Pens
- Canakinumab Subcutaneous-Insulin degludec and liraglutide
- Canakinumab Subcutaneous-Insulin degludec and liraglutide Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Canasa
- Insulin aspart, recombinant Subcutaneous-Canasa Pac rectal
- Insulin aspart, recombinant Subcutaneous-Canasa rectal
- Insulin aspart, recombinant Subcutaneous-Cancidas
- Insulin aspart, recombinant Subcutaneous-Candesartan
- Insulin aspart, recombinant Subcutaneous-Candesartan and Hydrochlorothiazide